- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05245682
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck Cancer
Study Overview
Status
Conditions
- Head and Neck Carcinoma of Unknown Primary
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Locally Advanced Laryngeal Squamous Cell Carcinoma
- Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
- Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Intervention / Treatment
Detailed Description
Primary Objective:
To evaluate the safety and tolerability of the recommended phase 2 dose (RP2D) of tolinapant when given in combination with radiation.
Secondary Objectives:
To assess preliminary efficacy of the combination of tolinapant and radiation in cisplatin ineligible patients with head and neck cancer as determined by locoregional control, two year progression-free survival (PFS), and two-year overall survival (OS).
Exploratory Objective:
To compare immune cell infiltrates following the first cycle of tolinapant + radiation, compared with baseline biopsy tissue and peripheral blood.
TERTIARY/EXPLORATORY OBJECTIVES:
I. To assess the effects of the combination of tolinapant + radiation on immune cells in blood and tumor.
II. To assess the association between immune responses and FADD expression in tumors.
OUTLINE:
Patients undergo standard of care radiation therapy for a total of 35 fractions over 6-7 weeks and receive tolinapant orally (PO) daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up 1, 3, 6, 12, and 24 months.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Nicole C Schmitt, MD
- Phone Number: 404-778-1900
- Email: nicole.cherie.schmitt@emory.edu
Study Contact Backup
- Name: Nabil F Saba, MD
- Email: nfsaba@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University/Winship Cancer Institute
-
Contact:
- Allyson Anderson
- Phone Number: 404-686-0239
- Email: allyson.anderson@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or Female.
- Age ≥18 years.
- ECOG performance status ≤1 (see Appendix A).
Patients with histologically or cytologically confirmed diagnosis of HNSCC, previously untreated and locally advanced, for whom definitive or adjuvant radiation is planned but cisplatin chemotherapy is contraindicated.
For the purposes of trial eligibility, anatomic subsites of HNSCC may include the larynx, oropharynx, hypopharynx, nasopharynx, or unknown primary site presenting with neck lymph nodal disease.
Patients must have a contraindication to cisplatin as defined below. The scores must be recorded on a CRF:
Age ≥ 70 with moderate to severe comorbidity, defined as having one or more of the following conditions within 30 days prior to registration:
- Modified Charlson Comorbidity Index ≥ 1
- ACE-27 Index ≥ 1
- G-8 score ≤ 14
- CARG Toxicity Score ≥ 30%
- CIRS-G Score ≥ 4 -OR-
Age ≥ 18 with an absolute or relative contraindication to cisplatin, defined as one or more of the following criterion within 30 days prior to registration:
- Pre-existing peripheral neuropathy grade ≥ 1;
- History of hearing loss, defined as either an existing need of a hearing aid OR moderate hearing loss as defined by the American Speech and Hearing Association (pretreatment audiogram showing 40-55 db HL hearing loss)
- Creatinine clearance (CrCl) must be > 30 and < 50 mL/min. For this calculation, use the Cockroft-Gault formula: CrCl = 0.85 (if female)* ((140-Age) / (Serum Creatinine)) * (Weight in kg / 72).
Acceptable organ function, as evidenced by the following laboratory data:
- Absolute neutrophil count [ANC] ≥ 1,500 cells/l; hemoglobin ≥ 9 g/dl, platelets ≥ 100,000/l.
- Serum creatinine ≤ 1.5 mg/dl, or calculated creatinine clearance ≥ 60 ml/min.
- Bilirubin ≤ upper limit normal [ULN], alanine aminotransferase [ALT] ≤ 1.5 x ULN and/or aspartate aminotransferase [AST] ≤ 1.5 x ULN, alkaline phosphatase ≤ 2.5 x ULN.
- Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.5 x ULN.
- Activated partial thromboplastin (aPTT) time ≤ 1.5 x ULN. Amylase and lipase ≤ ULN.
- The effects of tolinapant on the developing human fetus are unknown. For this reason and because tolinapant as well as other therapeutic agents used in this trial are known to be teratogenic, females of child-bearing potential (FCBP) must have a negative serum pregnancy test prior to starting therapy.
- Female patients of childbearing potential and men must agree to use adequate contraception (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study participation and for at least 6 months following study drug discontinuation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (if age > 55 years); if the female subject is < 55 years and she has been naturally postmenopausal for > 1 year her reproductive status has to be verified by additional lab tests (< 20 estradiol OR estradiol < 40 with FSH > 40 in women not on estrogen replacement therapy).
- Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol specified laboratory tests, other study procedures, and study restrictions.
- Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion Criteria:
- Patients who have had prior radiotherapy to the head and neck region
- Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of first dose of study drugs.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to tolinapant.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Significant cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure (or ejection fraction <50%); or uncontrolled Grade ≥3 hypertension (diastolic blood pressure ≥100 mmHg or systolic blood pressure ≥160 mmHg) despite antihypertensive therapy.
- Contraindications to radiotherapy (e.g. uncontrolled connective tissue disorder).
- Women who are pregnant or breast feeding.
- Vulnerable populations including prisoners and adults who are unable to consent.
- Known history of human immunodeficiency virus (HIV) infection, or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
- Grade 3 or greater neuropathy.
- Known distant metastases (i.e., outside of the neck).
- Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.
- Concurrent second malignancy requiring active therapy.
- Patients with a history of allogenic transplant must not have ≥Grade 3 graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic immunosuppression.
- Systemic corticosteroids >20 mg daily prednisone equivalent (unless patient has been taking a continuous dose for >3 weeks prior to study entry).
- Medications known to cause QT prolongation including some antipsychotics (chlorpromazine, haloperidol, droperidol, quetiapine, olanzapine, amisulpride, thioridazine), antiarrhythmics (quinidine, procainamide, disopyramide, flecanide, encainide, sotalol, amiodarone), antidipressants (amitriptyline, doxepin, imipramine, nortriptyline, desipramine), mianserin, citalopram, escitalopram, venlafaxine, bupropion, moclobemide), and antihistamines (diphenhydramine, astemizole, loratadine, terfenadine), macrolide antibiotics (erythromycin, clarithromycin), and antimalarials (chloroquine, hydroxychloroquine, quinine), unless the use of these drugs cannot be avoided.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (tolinapant, radiation therapy)
Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.
|
Undergo radiation therapy
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Tolinapant + Radiation (number of patients with adverse events per CTCAE v5.0)
Time Frame: Up to 30 days post-treatment
|
Safety will be assessed on clinical examination and measurement of laboratory parameters.
All safety assessments including adverse events, clinical laboratory evaluations, and vital signs will be summarized with descriptive statistics, where appropriate, and listed in the data listings using MedDRA terms.
|
Up to 30 days post-treatment
|
Feasibility of Tolinapant + Radiation (number of patients able to complete treatment)
Time Frame: Up to 2 years
|
Feasibility is defined as completion of treatment, which will be reported as a percentage, with a 95% exact confidence interval using the Clopper-Pearson method.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicole C Schmitt, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00002992
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Carcinoma of Unknown Primary
-
Shanghai Ninth People's Hospital Affiliated to...Shanghai Jiao Tong University School of MedicineUnknownHead-and-neck Cancer | Carcinoma of Unknown PrimaryChina
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI)Not yet recruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Unknown Primary CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Carcinoma of Unknown PrimaryUnited States
-
Mayo ClinicRecruitingHead and Neck Carcinoma | Metastatic Malignant Neoplasm in the Lymph Nodes | Nasal Cavity Carcinoma | Oral Cavity Carcinoma | Paranasal Sinus Carcinoma | Salivary Gland Carcinoma | Cutaneous Squamous Cell Carcinoma of the Head and Neck | Hypopharyngeal Carcinoma | Laryngeal Carcinoma | Oropharyngeal Carcinoma and other conditionsUnited States
-
Yale UniversityCompletedHead and Neck Cancer | Carcinoma of Unknown PrimaryUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingAdvanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell CarcinomaUnited States, Canada
-
University of MiamiCompletedHead and Neck Cancer | Carcinoma of Unknown PrimaryUnited States
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationCompletedUnknown Primary Cancer | Cancer of Unknown Primary Site | Unknown Primary, Squamous Cell CarcinomaDenmark
-
Ohio State University Comprehensive Cancer CenterRecruitingRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Non-melanomatous Skin Cancer | Carcinoma of Unknown PrimaryUnited States
Clinical Trials on Radiation Therapy
-
NRG OncologyNational Cancer Institute (NCI)RecruitingUnrectable or Locally Recurrent Hepatocellular CarcinomaUnited States
-
Medical College of WisconsinRecruitingHead and Neck CancerUnited States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of California, San FranciscoVarian Medical SystemsRecruitingStage IV Anal Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Postneoadjuvant Therapy Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumor | Central Nervous System TumorUnited States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
-
Medical College of WisconsinActive, not recruitingHigh-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB) (SIB)Prostate CancerUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina
-
NYU Langone HealthCompletedBreast CancerUnited States